Newsfeeds Archive - Page 7 of 7

4 minute read

Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday’s Mid-Day Session

September 13, 12:32 PM

Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis.

AAPL

2 minute read

Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

August 18, 6:19 PM

The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ:KRYS) Biologics License Application (BLA)…

AGLE

1 minute read

BridgeBio Starts Dosing In Early-Stage Genetic Metabolism Disorder Trial

By Vandana Singh

August 18, 8:53 AM

BridgeBio Pharma Inc (NASDAQ:BBIO) has dosed the first patient in its Phase 1 trial of BBP-671, an investigational oral therapy for…

BBIO

2 minute read

Recap Of Wednesday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

August 10, 6:23 PM

Bristol Myers Squibb (NYSE:BMY) and 2seventy bio (NASDAQ:TSVT) announced positive topline results from KarMMa-3, a Phase 3 study…

BBIO

2 minute read

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

August 3, 2:08 PM

ALNY

5 minute read

Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday

By Lisa Levin

July 27, 5:29 AM

Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1.

AAMC

4 minute read

Recap Of Tuesday’s Biotech Catalysts – End of The Day Summary

By Ragothaman Srinivasan

July 26, 6:24 PM

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg…

ABBV

1 minute read

SVB Leerink Maintains Outperform on BridgeBio Pharma, Raises Price Target to $30

By Benzinga Newsdesk

July 26, 9:24 AM

SVB Leerink analyst Mani Foroohar maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises the price target from $27 to $30.

BBIO